[Federal Register Volume 66, Number 229 (Wednesday, November 28, 2001)]
[Notices]
[Pages 59450-59451]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-29544]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Human Derived Monocyte 
Attracting Purified Peptide Products for Treating Human Infections and 
Neoplasms in a Human Body

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive license to practice the inventions embodied in the U.S. 
Patent Applications and Issued Patents listed below to AlleCure 
Corporation, having a place of business in Chatsworth, California. The 
patent rights of these inventions have been assigned to the United 
States of America.
     USPA 07/330,446 filed March 30, 1989 and entitled ``Human 
Derived Monocyte Attracting Purified Peptide Products Useful in a 
Method of Treating Infections and Neoplasms in a Human Body and the 
Cloning of Full Length cDNA Thereof''
     USPA 07/686,264 filed April 15, 1991 now USPN 6,090,795 
issued July 18, 2000

[[Page 59451]]

     USPA 08/449,552 filed May 24, 1995 now USPN 5,532,144 
issued July 2, 1996
     USPA 08/466,288 filed June 6, 1995 now USPN 5,714,578 
issued February 3, 1998
     PCT/US90/00040 filed January 2, 1990
    The prospective exclusive license territory will be worldwide and 
the field of use may be limited to the treatment of asthma, restenosis, 
hepatitis B and cancer.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before January 28, 
2002 will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comment and 
other materials relating to the contemplated exclusive license should 
be directed to: Percy S. Pan, Technology Licensing Specialist, Office 
of Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone 301-496-7736 
x256; Facsimile 301-402-0220; E-mail [email protected].

SUPPLEMENTARY INFORMATION: The invention relates to a human derived 
purified peptide product that exhibits monocytic chemotactic activity 
(MCA). A method of preparing the peptide is disclosed as well as a 
method of treating neoplasms and infections by administering the 
peptides. A pharmaceutical composition of the peptide is also claimed. 
The peptide may be useful in the treatment of various disorders 
including autoimmune disease, chronic inflammatory diseases, and 
cancer. This peptide, also known as MCP-1, is a b chemokine. Chemokines 
are multipotent cytokines that localize and enhance inflammation by 
inducting chemotaxis and activation of different types of inflammatory 
cells. This peptide is a chemotactic factor for monocytes. It 
stimulates histamine release and regulates cytokine production in 
monocytes.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establish that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and to the 
extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: November 15, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 01-29544 Filed 11-27-01; 8:45 am]
BILLING CODE 4140-01-P